|
1
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
|
|
2
|
Reardon JT, Vaisman A, Chaney SG and
Sancar A: Efficient nucleotide excision repair of cisplatin,
oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum
(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res.
59:3968–3971. 1999.
|
|
3
|
Lord RV, Brabender J, Gandara D, et al:
Low ERCC1 expression correlates with prolonged survival after
cisplatin plus gemcitabine chemotherapy in non-small cell lung
cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
|
|
4
|
Hallett RM, Pond G and Hassell JA: A
target based approach identifies genomic predictors of breast
cancer patient response to chemotherapy. BMC Med Genomics.
5:162012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Roock W, Claes B, Bernasconi D, et al:
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy
of cetuximab plus chemotherapy in chemotherapy-refractory
metastatic colorectal cancer: a retrospective consortium analysis.
Lancet Oncol. 11:753–762. 2010.PubMed/NCBI
|
|
7
|
Joensuu H, Kellokumpu-Lehtinen PL, Bono P,
et al: Adjuvant docetaxel or vinorelbine with or without
trastuzumab for breast cancer. N Engl J Med. 354:809–820. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flagella M, Bui S, Zheng Z, et al: A
multiplex branched DNA assay for parallel quantitative gene
expression profiling. Anal Biochem. 352:50–60. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ren GJ, Zhao YY, Zhu YJ, et al: Tumor gene
mutations and messenger RNA expression: correlation with clinical
response to icotinib hydrochloride in non-small cell lung cancer.
Chin Med J (Engl). 124:19–25. 2011.PubMed/NCBI
|
|
10
|
Asahina H, Yamazaki K, Kinoshita I,
Yokouchi H, Dosaka-Akita H and Nishimura M: Non-responsiveness to
gefitinib in a patient with lung adenocarcinoma having rare EGFR
mutations S768I and V769L. Lung Cancer. 54:419–422. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rosell R, Skrzypski M, Jassem E, et al:
BRCA1: a novel prognostic factor in resected non-small-cell lung
cancer. PLoS One. 2:e11292007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Joerger M, deJong D, Burylo A, et al:
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21
immunohistochemistry and clinical outcome in patients with advanced
non small-cell lung cancer receiving first-line
platinum-gemcitabine chemotherapy. Lung Cancer. 74:310–317. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Johnston PG, Lenz HJ, Leichman CG, et al:
Thymidylate synthase gene and protein expression correlate and are
associated with response to 5-fluorouracil in human colorectal and
gastric tumors. Cancer Res. 55:1407–1412. 1995.PubMed/NCBI
|
|
15
|
Ceppi P, Volante M, Saviozzi S, et al:
Squamous cell carcinoma of the lung compared with other histotypes
shows higher messenger RNA and protein levels for thymidylate
synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakagawa T, Otake Y, Yanagihara K, et al:
Expression of thymidylate synthase is correlated with proliferative
activity in non-small cell lung cancer (NSCLC). Lung Cancer.
43:145–149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bepler G, Kusmartseva I, Sharma S, et al:
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and
platinum in non-small-cell lung cancer. J Clin Oncol. 24:4731–4737.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seve P, Isaac S, Tredan O, et al:
Expression of class III {beta}-tubulin is predictive of patient
outcome in patients with non-small cell lung cancer receiving
vinorelbine-based chemotherapy. Clin Cancer Res. 11:5481–5486.
2005.
|
|
19
|
Franklin WA, Veve R, Hirsch FR, Helfrich
BA and Bunn PA Jr: Epidermal growth factor receptor family in lung
cancer and premalignancy. Semin Oncol. 29:3–14. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jourdain L, Curmi P, Sobel A, Pantaloni D
and Carlier MF: Stathmin: a tubulin-sequestering protein which
forms a ternary T2S complex with two tubulin molecules.
Biochemistry. 36:10817–10821. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Knoop AS, Knudsen H, Balslev E, et al:
Retrospective analysis of topoisomerase IIa amplifications and
deletions as predictive markers in primary breast cancer patients
randomly assigned to cyclophosphamide, methotrexate, and
fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:
Danish Breast Cancer Cooperative Group. J Clin Oncol. 23:7483–7490.
2005.
|
|
22
|
Nielsen KV, Ejlertsen B, Moller S, et al:
The value of TOP2A gene copy number variation as a biomarker in
breast cancer: Update of DBCG trial 89D. Acta Oncol. 47:725–734.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lewis SJ, Cherry NM, Niven RM, Barber PV
and Povey AC: Associations between smoking, GST genotypes and
N7-methylguanine levels in DNA extracted from bronchial lavage
cells. Mutat Res. 559:11–18. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sorensen M, Autrup H, Tjonneland A,
Overvad K and Raaschou-Nielsen O: Glutathione S-transferase T1
null-genotype is associated with an increased risk of lung cancer.
Int J Cancer. 110:219–224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Woenckhaus M, Merk J, Stoehr R, et al:
Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small
cell lung cancer. Hum Pathol. 39:126–136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barberis M, Pellegrini C, Cannone M,
Arizzi C, Coggi G and Bosari S: Quantitative PCR and HER2 testing
in breast cancer: a technical and cost-effectiveness analysis. Am J
Clin Pathol. 129:563–570. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamura H, Saji H, Ogata A, et al:
Correlation between encoded protein overexpression and copy number
of the HER2 gene with survival in non-small cell lung cancer. Int J
Cancer. 103:61–66. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cox G, Vyberg M, Melgaard B, Askaa J,
Oster A and O’Byrne KJ: Herceptest: HER2 expression and gene
amplification in non-small cell lung cancer. Int J Cancer.
92:480–483. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakamura H, Kawasaki N, Taguchi M and
Kabasawa K: Association of HER-2 overexpression with prognosis in
nonsmall cell lung carcinoma: a metaanalysis. Cancer.
103:1865–1873. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sarlomo-Rikala M, Kovatich AJ,
Barusevicius A and Miettinen M: CD117: a sensitive marker for
gastrointestinal stromal tumors that is more specific than CD34.
Mod Pathol. 11:728–734. 1998.PubMed/NCBI
|
|
31
|
Heinrich MC, Corless CL, Duensing A, et
al: PDGFRA activating mutations in gastrointestinal stromal tumors.
Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamamoto H, Oda Y, Kawaguchi K, et al:
c-kit and PDGFRA mutations in extragastrointestinal stromal tumor
(gastrointestinal stromal tumor of the soft tissue). Am J Surg
Pathol. 28:479–488. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vlahovic G, Rabbani ZN, Herndon JE II,
Dewhirst MW and Vujaskovic Z: Treatment with Imatinib in NSCLC is
associated with decrease of phosphorylated PDGFR-beta and VEGF
expression, decrease in interstitial fluid pressure and improvement
of oxygenation. Br J Cancer. 95:1013–1019. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singhal S, Vachani A, Antin-Ozerkis D,
Kaiser LR and Albelda SM: Prognostic implications of cell cycle,
apoptosis, and angiogenesis biomarkers in non-small cell lung
cancer: a review. Clin Cancer Res. 11:3974–3986. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang JC, Haworth L, Sherry RM, et al: A
randomized trial of bevacizumab, an anti-vascular endothelial
growth factor antibody, for metastatic renal cancer. N Engl J Med.
349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Paik S, Kim C and Wolmark N: HER2 status
and benefit from adjuvant trastuzumab in breast cancer. N Engl J
Med. 358:1409–1411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang YK, Yeager RL and Klaassen CD:
Circadian expression profiles of drug-processing genes and
transcription factors in mouse liver. Drug Metab Dispos.
37:106–115. 2009. View Article : Google Scholar : PubMed/NCBI
|
